

## Solid Tumour Request Form: Endometrial Cancer

Fill in patient details below – or affix addressograph (top left)									
Patient Forename:							Pathologist (address report to):		
Patient Surname:						Requ	Requested by:		
DoB:				NHS number:		Hosp	ospital Name ( <u>essential for report</u> )		
Sex:							<b>Email Addresses (for reports):</b> (NHS Wales or NHS.net) oncologists/pathologists/MDT		
Address:				Alternative Hospital no:			coordinators )		
			-	Date requested:					
Postcode:				Duce requested.					
Please note: Gene analysis relies on sampling <u>tumour tissue</u> . Tissues blocks for genomic analysis can no longer be accepted.									
This section is for completion by Pathology Laboratory.									
Pathologist:				Pathology Hospital:			Block Number:		
Sampling method, biopsy type and fixation			fixation m	method. Date sample sent to A			GS	Tumour sample now exhausted	
							Yes □ No □		
For ALL requests please provide:   1 H&E stained slide with area of highest neoplastic cell content CLEARLY circled.   Please state the approx. % neoplastic cell content present in the H&E circled tumour area:									
<b>Relevant Clinical Summary</b> (e.g. tumour histology) <i>Please also attach appropriate pathology report</i>									
Test Test di			Test dire	rectory Technology			Sample requirements		
<b>POLE</b> – sequence ana of exons 9-14	lysis		M215.5		TSO500 DNA NGS Panel		60μM (preferably <b>6 x 10μM</b> ) air dried unstained sections mounted on slides		
<b>TP53</b> – sequence ana of entire coding regio					TSO500 DNA NGS Pane	iel Estima		ted neoplastic cell proportion ≥ <b>10%</b> required for the <b>TSO500</b> assay	
MLH1 promoter methylation analysis			M215.2		Bisulphite pyrosequencing		Estimated neoplastic cell proportion ≥20% required for MLH1 promoter methylation analysis.		
In the event of insufficient tissue/low cellularity/low neoplastic cell content samples, please discuss with AWMGS appropriate alternate routes of testing before sending samples									
Samples should be dispatched as soon as possible as the patient's treatment is dependent upon the molecular analysis									
For further information on testing and further details on panels used please, refer to the AWMGL website: <u>https://www.medicalgenomicswales.co.uk/</u>									
Please complete this request form and send with the sample to:									
		A	ll Wales Me	edical Genor	nics Laboratory, Institute	e of Me	edical	Genetics,	
La	borato	ry contac			l <b>of Wales, Heath Park, C</b> : Phone – 029 2184 264			xw o.genetics@wales.nhs.uk	